Study Subject Participation Status | Clinical Trial adalimumab
Item
participation and completion until week 24 of the prior adalimumab dose-ranging study.
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C1122087 (UMLS CUI [2,2])
Gender Postmenopausal state | Female Sterilization | Gender Contraceptive methods
Item
females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion.
boolean
C0079399 (UMLS CUI [1,1])
C0232970 (UMLS CUI [1,2])
C0015787 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Childbearing Potential Serum pregnancy test negative
Item
female subjects tested negative in pregnancy test (serum test) at week 24 in prior adalimumab study, if capable of pregnancy.
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
criteria Fulfill
Item
a subject who experienced any of the following during prior study:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Diabetes Mellitus Advanced | Diabetes mellitus poor control
Item
advanced or poorly controlled diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0860161 (UMLS CUI [2])
Operation on joint
Item
joint surgery (joint evaluated in this study)
boolean
C0185132 (UMLS CUI [1])
Pharmaceutical Preparations Excluded prescribed
Item
a subject who has been prescribed excluded medications during prior study.
boolean
C0013227 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
C0278329 (UMLS CUI [1,3])
Medical History
Item
history of following during prior study:
boolean
C0262926 (UMLS CUI [1])
Substance Use Disorders Clinical Significance
Item
clinically significant drug or alcohol abuse
boolean
C0038586 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
Intravenous Drug Abuse
Item
intravenous (iv) drug abuse
boolean
C0086181 (UMLS CUI [1])
Listeriosis | Tuberculosis
Item
active infection with listeria or tuberculosis (tb)
boolean
C0023860 (UMLS CUI [1])
C0041296 (UMLS CUI [2])
Lymphoma | leukemia
Item
lymphoma, leukemia
boolean
C0024299 (UMLS CUI [1])
C0023418 (UMLS CUI [2])
Malignant Neoplasms | Basal cell carcinoma Treated Successful
Item
and, any malignancy with the exception of successfully treated non-metastatic basal cell carcinoma of the skin.
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C1272703 (UMLS CUI [2,3])
Vaccines, Attenuated | Attenuated Vaccines Planned
Item
a subject who has been administered a live vaccine during prior study, or subject scheduled to complete the administration of a live vaccine during the study period
boolean
C0042211 (UMLS CUI [1])
C0042211 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])